TY  - CHAP
M1  - Book, Section
TI  - Human Immunodeficiency Virus Infection
A1  - Anderson, Peter L.
A1  - Kakuda, Thomas N.
A1  - Fletcher, Courtney V.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateApril  4,  2019New  guideline  recommendations  regarding  prophylaxis  in  Pneumocystis  pneumonia  (PCP)  and  Mycobacterium  avium  complex  (MAC)  disease:  The  U.S.  Department  of  Health  and  Human  Services  (DHHS)  Guidelines  for  the  Prevention  and  Treatment  of  Opportunistic  Infections  in  Adults  and  Adolescents  with  HIV  were  updated  in  early  2019.  Among  the  updates  included  in  this  guideline  issue  were  recommendations  for  when  to  discontinue  prophylaxis  (both  primary  and  secondary)  for  PCP  and  the  decision  to  initiate  primary  prophylaxis  for  MAC.  Guidelines  now  support  the  discontinuation  of  PCP  prophylaxis  (primary  or  secondary)  in  patients  with  an  undetectable  viral  load  and  a  CD4  count  between  100  –  200  cells/mm3  for  3-6  months  (BII  rating).  Additionally,  the  panel  no  longer  recommends  primary  prophylaxis  for  MAC  in  patients  able  to  initiate  antiretroviral  therapy  (ART)  immediately  regardless  of  CD4  cell  count  (AII  rating).  Healthcare  providers  should  carefully  interpret  updated  guidelines  and  integrate  into  clinical  practice.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1164182195
ER  -